Visine Long Lasting and Zyvox (Linezolid Suspension)
Determining the interaction of Visine Long Lasting and Zyvox (Linezolid Suspension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using oxymetazoline ophthalmic together with linezolid may increase cardiovascular side effects such as blood pressure elevations and increased heart rate. Talk to your doctor if you have any questions or concerns, especially if you have a history of high blood pressure, irregular heart rhythm, or heart disease. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically absorbed sympathomimetic agents following topical administration (e.g., nasal decongestants, ophthalmic vasoconstrictors). However, the interaction has not been reported extensively in the medical literature. No increase in blood pressure or heart rate was observed when tranylcypromine was administered to a patient using 1% epinephrine eye drop twice a day. Most topical decongestants and vasoconstrictors are direct-acting sympathomimetics, which appear to be less affected by MAOIs than indirect- or mixed-acting sympathomimetics such as pseudoephedrine or ephedrine. While MAOI use has been reported to precipitate severe hypertensive reactions and hyperpyrexia in patients receiving indirect- or mixed-acting agents, most studies have found minimal effect on pressor response to systemically administered direct-acting agents including epinephrine, norepinephrine, and isoproterenol. Nevertheless, increased pressor effects and greater than 50% reductions in the required dosage of direct-acting agents have been reported in hypertensive patients who were being treated for MAOI-induced postural hypotension. There have also been occasional reports of increased blood pressure and heart rate in patients receiving systemic direct-acting agents and MAOIs.
MANAGEMENT: Although data are limited, caution may be advisable when topical decongestants and vasoconstrictors are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).
- Thompson DS, Sweet RA, Marzula K, Peredes JC "Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient." J Clin Psychopharmacol 17 (1997): 322-3
- Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7
- Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
- Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62
- Fenwick MJ, Muwanga CL "Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline." J Accid Emerg Med 17 (2000): 143-4
- Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
- De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
- Elis J, Laurence DR, Mattie H, Prichard BN "Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure." Br Med J 2 (1967): 75-8
- Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5
- Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5
- Smookler S, Barmudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant." Ann Emerg Med 11 (1982): 482-4
- Goulet JP, Perusse R, Turcotte JY "Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions." Oral Surg Oral Med Oral Pathol 74 (1992): 692-7
- Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6
- Sjoerdsma A "Catecholamine-drug interactions in man." Pharmacol Rev 18 (1966): 673-83
- Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
Generic Name: oxymetazoline ophthalmic
Brand name: Visine LR, Visine Long Lasting, Ocuclear
Synonyms: Visine L.R.
Generic Name: linezolid
Brand name: Zyvox
Synonyms: Zyvox
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Visine Long Lasting-Zyvox (Linezolid Tablets)
- Visine Long Lasting-Zyvox Injection
- Visine Long Lasting-Zyvox Intravenous
- Visine Long Lasting-ZzzQuil
- Zyvox (Linezolid Suspension)-Visine Maximum Redness Relief
- Zyvox (Linezolid Suspension)-Visine Multi-Symptom Relief
- Zyvox (Linezolid Suspension)-Visine Totality
- Zyvox (Linezolid Suspension)-Visine-A
- Zyvox (Linezolid Suspension)-Vision Clear
- Zyvox (Linezolid Suspension)-Visipaque